SCHEMBL7582210

SCHEMBL7582210

CCO[C@H]1[C@H](OCc2ccccc2)[C@@H](NC(C)=O)[C@@H](OCc2ccccc2)O[C@@H]1COCc1ccccc1

nearest known ligand 0.55

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
TP53 P04637 2/20 0.55
MDM2 Q00987 2/20 0.55
POLB P06746 1/20 0.52
MDM4 O15151 1/20 0.50
HSP90AA1 P07900 1/20 0.50
HSP90AB1 P08238 1/20 0.50
TACR2 P21452 2/20 0.49
NT5E P21589 1/20 0.49
PTPN1 P18031 8/20 0.49
CDC25B P30305 7/20 0.49
LMNA P02545 1/20 0.48
KMT2A Q03164 1/20 0.48
L3MBTL1 Q9Y468 1/20 0.48
PTPN2 P17706 4/20 0.47
PTPN6 P29350 4/20 0.47
PTPN11 Q06124 4/20 0.47
BCHE P06276 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5840927 0.97 TP53 (0.55) TP53MDM2POLBMDM4HSP90AA1
SCHEMBL16967451 0.97 TP53 (0.55) TP53MDM2POLBMDM4HSP90AA1
SCHEMBL15514084 0.97 TP53 (0.55) TP53MDM2POLBMDM4HSP90AA1
SCHEMBL5840884 0.97 TP53 (0.55) TP53MDM2POLBMDM4HSP90AA1
SCHEMBL11173059 0.93 TP53 (0.52) TP53MDM2POLBMDM4HSP90AA1
SCHEMBL13491599 0.93 POLB (0.52) TP53MDM2POLBMDM4HSP90AA1
SCHEMBL7583524 0.93 POLB (0.52) TP53MDM2POLBMDM4HSP90AA1
SCHEMBL16628842 0.92 L3MBTL1 (0.58) TP53MDM2POLBMDM4HSP90AA1
SCHEMBL16628841 0.92 L3MBTL1 (0.58) TP53MDM2POLBMDM4HSP90AA1
SCHEMBL6760496 0.91 POLB (0.63) TP53MDM2POLBMDM4HSP90AA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020137791-A1 NEURAMINIC ACID DERIVATIVES, THEIR PREPARATION AND THEIR MEDICAL USE SANKYO COMPANY, LIMITED (JP) 2002-09-26 US disclosed
US-6451766-B1 SIALIDASE INHIBITORS; INFLUENZA VIRICIDES SANKYO COMPANY, LIMITED (JP) 2002-09-17 US disclosed
US-6340702-B1 SIALIDASE INHIBITORS; ANTIVIRAL COMPOUNDS SANKYO COMPANY, LIMITED (JP) 2002-01-22 US disclosed
EP-0823428-B1 Neuraminic acid derivatives, their preparation and their medical use SANKYO CO (JP) 2002-01-02 EP disclosed
EP-0823428-A2 Neuraminic acid derivatives, their preparation and their medical use SANKYO COMPANY LIMITED (JP) 1998-02-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020137791-A1 NEURAMINIC ACID DERIVATIVES, THEIR PREPARATION AND THEIR MEDICAL USE NEU1, NEU3, NEU2 TP53 4767/4885MDM2 4193/4885POLB 1576/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.